glp-1 news today obesity drug updates New research is challenging long-held assumptions about GLP 3 Takeaways from the Landmark

Once-daily oral semaglutide (Rybelsus) achieves an HbA 1c reduction of around 1115 mmol/mol in people with type 2 diabetes less than injectable semaglutide but comparable to other long-acting injectable GLP-1 RAs

Dahl K, Brooks A, Almazedi F, Hoff ST, Boschini C, Baekdal TA

This aligns with mechanistic studies showing that dipyridamole dampens aberrant monocyte/macrophage activation and may protect against progression to clonal hematopoiesis or histiocytic disorders

At the same time, type 1 diabetes is experiencing an unexplained epidemic, with its prevalence steadily rising since the 2010s

Although a high dose of semaglutide reduces alcohol intake in male rats (Marty et al., 2020), additional preclinical studies are needed to explore the effects of semaglutide on alcohol drinking in various preclinical models of AUD in rats of both sexes

Key Market Insights Highlight Strong Demand Across Products and Applications By Product Type , Ozempic was the market leader with a market share of about 35.12% in 2025 based on proven clinical evidence, wide adoption by physicians, cardiovascular benefit, and strong commercial presence